formerly nonalcoholic fatty liver disease) affects about 25% of adults globally.68 In people living with obesity, the prevalence of MASLD is about 75%, with MASH (formerly nonalcoholic steatohepatitis) affecting about 34%.69 Metabolic dysfunctionassociated steatotic liver disease is strongly associated with cardiometabolic risk factors.70 Its management is focused on weight loss in people with obesity;71 optimization of cardiometabolic risk factors
IBS-D, irritable bowel syndrome diarrhea
In this paper, it is the floor
Were the only specialized global platform helping patients get treatments unavailable in their countries
Structural problems, degenerative conditions, and issues requiring surgical intervention fall outside its primary applications
These products fall outside the regulated pharmaceutical supply chain, meaning quality verification through third-party testing and certificates of analysis becomes essential